UPDATE: Jefferies Initiates Verastem at Buy on Cancer Research Potential

In a report published Monday, Jefferies analyst Biren Amin initiated coverage on Verastem VSTM with a Buy rating and $21.00 price target.

In the report, Jefferies noted, “VSTM's R&D focus is the development of drugs targeting cancer stem cells. VSTM will begin a registration-directed PII trial for its lead candidate, VS-6063 (FAK inhibitor), in mesothelioma that we believe has favorable odds of showing a PFS benefit, supporting potential accelerated approval in H2'16. We are initiating coverage of VSTM with a Buy and $21 PT.”

Verastem closed on Friday at $14.78.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorInitiationAnalyst RatingsBiren AminJefferies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!